First-half revenues have climbed a third at Sinclair IS Pharma, which also said it was confident of a strong second-half performance
The Chester-based pharmaceutical company revealed that revenues increased by 31 per cent to £32m in the six months ending 31 December 2014.
However, the business also reported pre-tax losses of £10.8m compared to £2.5m a year earlier, which it attributed mainly to a £7.7m increase in finance charges arising from acquisitions in the 2014 financial year.
Chris Spooner, CEO of Sinclair IS Pharma, said: "Sinclair is positioned as a mixed aesthetic and medicinal dermatology business, but with the bulk of growth expected to come from higher margin aesthetics. H1 FY15 saw strong growth in aesthetic sales in Europe which were partly offset by a weaker Euro and political difficulties in Russia.
"However accelerating growth towards the end of the period, in-market demand and demand for training give us confidence in a strong H2 performance.
"Additionally, geographical expansion, and anticipated product approvals point to further attractive growth opportunities in the medium term."